These data suggest that CDK6 is involved in the advance stages (from stage II to IV) of BLCA and meaningful to be detected by IHC for evaluating prognosis and therapeutical potential of CDK4/6 inhibitors in these populations. The gene discussed is CDK4; the disease is bladder transitional cell carcinoma.